Susan Moran
Director/Board Member at BIOATLA, INC.
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Todd Harris | M | 44 | 6 years | |
| Jay Short | M | 66 | 17 years | |
| Scott Smith | M | 61 | 6 years | |
| Daniel Bensen | M | 49 | 6 years | |
| Carolyn Anderson Short | F | 59 | 17 years | |
| Christian Vasquez | M | 48 | 9 years | |
| Robert Hudkins | M | 69 | 4 years | |
| Nina Kjellson | F | 49 | 6 years | |
| Rehan Verjee | M | 43 | 3 years | |
| Robert More | M | 56 | 6 years | |
| Melissa McCracken | M | 37 | 3 years | |
| Siddarth Subramony | M | 37 | 4 years | |
| Jake Simson | M | 38 | 4 years | |
| Kimberly McCutcheon Jablonski | F | - | - | |
| Mary Gray | M | 71 | 4 years | |
| Adrian Senderowicz | M | 60 | 9 years | |
| Sylvia Mcbrinn | F | 71 | 3 years | |
| Edward Williams | M | 68 | 3 years | |
| Amy Conrad | F | - | - | |
| Sandra Ramos-Alves | F | - | - | |
| Lawrence Steinman | M | 76 | 8 years | |
| Gilla Kaplan | M | 76 | 5 years | |
| Ali Fawaz | M | - | 2 years | |
| George Melko | M | - | - | |
| Gerhard Frey | M | - | 17 years | |
| Jennifer Davis | F | - | - | |
| Allison Kemner | F | - | - | |
| Hiroomi Tada | M | - | 4 years | |
| Piyush Patel | M | 59 | 3 years | |
| Melissa Neal | F | - | - | |
| Ronald Swanson | M | - | 5 years | |
| Rick Panicucci | M | 63 |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | 6 years |
| Sophia Park | F | - | - | |
| Susie Melody | F | - | - | |
| Craig Berman | M | - |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | 6 years |
| Douglas Hunt | M | 59 | 6 years | |
| Benjamin Hickey | M | 50 | - | |
| Cathy Chang | M | - | - | |
| Konstantina Katcheves | F | - | - | |
| Mike Melnick | M | - | - | |
| Eric Sievers | M | 60 | 5 years | |
| William J. Boyle | M | - | 11 years | |
| Richard Waldron | M | 70 | 13 years | |
| Alan Fuhrman | M | 67 | 1 years | |
| Sarah Honig | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Deborah Dunsire | M | 61 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 8 years |
| Richard Benton Phillips | M | 70 | 3 years | |
| Kenneth Song | M | 49 | 4 years | |
| Laurie Keating | F | 70 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 10 years |
| Aaron Kantoff | M | 29 | 4 years | |
| Aaron Royston | M | 40 | 3 years | |
| Tim van Hauwermeiren | M | 52 | 1 years | |
| Philippe Martin | M | - | 5 years | |
| Guy Levy | M | 42 | 2 years | |
| Maha Katabi | M | 50 | 2 years | |
| Nancy Simonian | M | 63 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 10 years |
| Isan Chen | M | 61 | 5 years | |
| Andrew Franklin | M | 58 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 2 years |
| Arvind Kush | M | 41 | 3 years | |
| Frank Zavrl | M | 58 | 5 years | |
| Thomas Malley | M | 55 | 4 years | |
| Mary Tagliaferri | M | 58 | 3 years | |
| Yi Larson | F | 44 | 3 years | |
| Richard A. Moscicki | M | 72 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 2 years |
| Yaping Shou | M | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 7 years |
| Jacquelyn Sandell | F | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 4 years |
| Dirk Huebner | M | 61 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 6 years |
| Robert Charnas | M | 70 | - | |
| Karin Ann Thacker | F | - | 1 years | |
| Matthew Rossen | M | 47 |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | 2 years |
| Karen Brennan | F | 68 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 7 years |
| Brian Barnett | M | 53 | 3 years | |
| Jerald Korn | M | 45 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 2 years |
| Richard Williams | M | 55 | 3 years | |
| Rachael Brake | M | 52 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 7 years |
| Jeffrey Woodley | M | - | - | |
| Alex Rosen | M | 35 | 2 years | |
| Santhosh Palani | M | 41 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 1 years |
| Christy Oliger | F | 54 | 1 years | |
| Brendan James Martin | M | - |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | - |
| Hiromichi Kimura | M | 73 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 1 years |
| Sandy Smith | M | 77 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 15 years |
| Tariq Kassum | M | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 2 years |
| Angie You | M | 51 | 2 years | |
| Richard Heyman | M | 66 | 2 years | |
| Ely Benaim | M | 63 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 2 years |
| Kyle Kuvalanka | M | 56 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 4 years |
| Eric Bischoff | M | - | - | |
| Antonio Gualberto | M | 59 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 2 years |
| Steven Lo | M | 57 | 4 years | |
| Claire Thomas | M | 68 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 5 years |
| Karen Ferrante | M | 66 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 6 years |
| Daniel Curran | M | 57 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 13 years |
| Manisha Pai | F | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 5 years |
| Erin Jones | M | 52 | 2 years | |
| Rozalyn Littler | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 92 | 95.83% |
| United Kingdom | 4 | 4.17% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Susan Moran
- Personal Network
